BioStock: Abliva’s KL1333 development plan receives OK from FDA

As Abliva prepares for its next steps in the clinical development of KL1333, the company has received good news from FDA. At a pre-Investigational New Drug meeting, FDA presented positive feedback to Abliva’s plans for continuation with the project aimed at developing a new treatment of primary mitochondrial diseases.

Read the full article at biostock.se:

https://www.biostock.se/en/ablivas-kl1333-development-plan-receives-ok-from-fda/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se